-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $3.5

Benzinga·09/29/2026 09:31:49
Listen to the news
Roth Capital analyst Max Masucci initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and announces Price Target of $3.5.